Oral physiological magnesium supplementation for 6 weeks with 1 g/d magnesium oxide does not affect increased Lp(a) levels in hypercholesterolaemic subjects.
Twenty hyperlipidaemic patients on a cholesterol-poor diet were selected on the basis of a raised lipoprotein (a) (Lp(a); apo (a) > 300 U/litre) and treated with 1000 mg MgO per day during 6 weeks. Serum magnesium slightly increased compared to pretreatment levels (P < 0.001). Serum apo(a) concentrations (mean +/- S.D.) were not affected: pretreatment level 963 +/- 552 U/litre; during treatment 999 +/- 536 U/litre; and after washout 995 +/- 524 U/litre. Serum cholesterol increased slightly during MgO treatment because of an increase in LDL-cholesterol (10 per cent) and returned to pretreatment levels after a washout period.
Hoogerbrugge
N
N
Lipid Clinic, University Hospital Rotterdam Dijkzigt, The Netherlands.
Cobbaert
C
C
de Heide
L
L
Birkenhäger
J C
JC
D000284:Administration, Oral; D001054:Apolipoproteins A / Q000187:drug effects / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000097:blood / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects; D008274:Magnesium / Q000097:blood; D008277:Magnesium Oxide / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D011446:Prospective Studies; D014280:Triglycerides / Q000378:metabolism
D001054:Apolipoproteins A; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D008277:Magnesium Oxide; D002784:Cholesterol; D008274:Magnesium